Efficacy evaluation of TACE combined with regorafenib and PD-1 inhibitors as the second-line treatment for advanced liver cancer
Objective To investigate the efficacy and adverse reactions of combined transarterial chemoembolization(TACE),regorafenib and PD-1 inhibitors as the second-line treatment for advanced hepatocellular carcinoma(HCC).Methods A total of 49 patients with advanced HCC who received TACE combined with regorafenib and PD-1 inhibitors or TACE combined with regorafenib as the second-line treatment from December 2018 to April 2024 were collected.Among them,23 patients received TACE combined with regorafenib and PD-1 inhibitors,and 26 patients received TACE combined with regorafenib.The modified RECIST criteria were used to evaluate the short-term efficacy.The patients'short-term efficacy,long-term efficacy,and adverse reactions were observed.Results The effective rates of TACE combined with regorafenib and PD-1 inhibitors and TACE combined with regorafenib were 34.8%and 15.4%(P>0.05),respectively.The disease control rates were 73.9%and 46.2%(P<0.05),respectively.The median progression-free survival was 7 months and 4 months(P<0.05),respectively.The median overall survival was 15 months and 11 months(P<0.05),respectively.The main adverse reactions in the both two groups were hand-foot syndrome,fatigue,fever and diarrhea,which were mostly of grade 1-2.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with TACE combined with regorafenib,TACE combined with regorafenib and PD-1 inhibitors has better efficacy and the safety is controllable.
NETL
NSTL
万方数据
